Platelet-Like Particle Development

The contract seeks the design and validation of synthetic or bioengineered particles engineered to replicate the essential functions of platelets in trauma scenarios, specifically focusing on clot initiation, adhesion to damaged vasculature, and aggregation to form stable hemostatic plugs. These particles must be validated through rigorous in vivo testing to demonstrate efficacy under physiologically relevant conditions, with an emphasis on rapid response in high-blood-flow, high-stress trauma environments where conventional treatments may fail. The technology must be scalable, stable, and capable of integration into existing medical protocols for battlefield or emergency use. Performance will be directed by the Defense Advanced Research Projects Agency under the Department of Defense, with the project classified as a subcontract under NAICS code 325412, indicating an emphasis on pharmaceutical and medicinal chemistry manufacturing. Proposals are due by May 19, 2026, and the work is expected to advance the state of the art in trauma care through novel biomaterials that bridge the gap between synthetic engineering and biological function. The goal is to create a shelf-stable, off-the-shelf therapeutic alternative to donated platelets that can be deployed immediately in austere or combat environments without refrigeration or compatibility testing.